Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Pacific Biosciences (PACB): Analyst Consensus Points to +48% Upside Toward $2.70 Target

Pacific Biosciences (PACB): Analyst Consensus Points to +48% Upside Toward $2.70 Target

Key Takeaways

  • The central target of $2.70 is the arithmetic mean of six verified analyst price targets reviewed for this article, spanning a low of $2.00 to a high of $3.00.
  • With Pacific Biosciences of California, Inc. (PACB) recently trading near $1.82, reaching $2.70 would require a gain of roughly 48% — a substantial move.
  • Analyst opinion is genuinely split: Buy-rated firms carry $3.00 targets, while Barclays holds an Underweight rating with a $2.00 target, reflecting disagreement over near-term execution risk versus long-term sequencing potential.
  • The strongest supporting factors are rebounding instrument sales, record consumables revenue, and the planned rollout of the lower-cost SPRQ-Nx chemistry and multi-use SMRT cells.
  • The biggest risks are sustained cash burn, a sizable convertible-debt load, competition in sequencing, and the possibility of a near-term "air pocket" in consumables demand ahead of new product launches.
  • Readers can explore Major News, Today's Price Move, the Forecast, and Earnings pages for additional detail on this ticker.
  • For automated, data-driven market insight, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Six current analyst targets were reviewed to establish the central target. They range from $2.00 to $3.00, and their arithmetic mean is $2.70. Among the most recent revisions, UBS lowered its target to $2.70 from $3.05 while keeping a Neutral rating, and Piper Sandler (David Westenberg) raised its target to $3.00 from $2.00 while staying Neutral. Canaccord Genuity maintained a Buy rating with a $3.00 target, Stephens (Mason Carrico) lifted its Overweight target to $2.50, and TD Cowen held a Buy rating with a $3.00 target. On the cautious side, Barclays (Luke Sergott) raised its target to $2.00 from $1.25 but kept an Underweight rating, arguing the shares face a "tough setup" as customers may pause consumables purchases ahead of the SPRQ-Nx launch. The wide $1.00 spread between the lowest and highest targets reflects a core debate: whether PacBio's long-term long-read sequencing opportunity outweighs near-term execution and funding risks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

PACB recently traded near $1.82, within a 52-week range of $1.07 to $3.44 that illustrates its extreme volatility. Reaching $2.70 would require a gain of roughly 48%, a substantial move that would still leave the shares well below their October 2026 peak. The company's fundamentals remain challenged: trailing revenue of about $161 million against a roughly -81% net margin, negative EPS (earnings per share) of about -$0.43, and a market capitalization near $570 million. The path toward $2.70 hinges on converting a recent operational inflection — a rebound in instrument placements and record consumables sales — into sustained revenue growth, while investors weigh persistent cash burn and heavy debt against the promise of new chemistry that could lower sequencing costs and broaden adoption.

What Could Support a Move Toward the Target

Several verified developments support the bull case. Third-quarter 2026 revenue of about $40.6 million rose 6% year over year and was broadly in line with expectations, with instrument demand described as a bright spot, particularly in Europe. Management has pointed to record consumables revenue and a rebound in instrument sales as evidence of an emerging inflection. The planned commercial rollout of multi-use SMRT (single-molecule real-time) cells and the new SPRQ-Nx chemistry are intended to reduce sequencing costs and expand use cases. Growing clinical adoption — including collaborations in rare disease and unexplained pediatric mortality — adds a longer-term demand channel, and institutional buying from innovation-focused investors has supported sentiment.

What Could Prevent the Target From Being Reached

The risks are equally concrete. PacBio continues to burn cash, posting negative EBITDA (earnings before interest, taxes, depreciation, and amortization) and net losses, and carries a meaningful convertible-debt burden that could pressure the balance sheet. Competition from larger sequencing players such as Illumina (ILMN) is intense, and analysts at Barclays have warned of a potential pause in consumables demand as customers await competitive launches and the SPRQ-Nx transition. Uncertain research funding, including NIH-related pressures, has historically weighed on demand, and the company's negative equity position and extreme beta underscore the downside sensitivity of the stock if execution stalls.

Technical Levels and Market Structure

PACB's chart is defined by sharp swings rather than a stable trend. The 52-week high near $3.44, set in October 2026, marks the most recent major resistance, while the 52-week low near $1.07 from August 2026 remains the cycle floor. The $2.00 level serves as both the lowest analyst target and a round psychological reference point, and the cluster of targets between $2.50 and $3.00 represents a zone where the shares would encounter meaningful overhead supply. A sustained move toward $2.70 would require clearing the recent post-earnings decline and holding above the $1.73–$1.82 area that has acted as near-term support.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may differ. The most relevant upcoming items include the next quarterly earnings report and guidance, the commercial launch and early adoption of SPRQ-Nx chemistry, and any analyst target or rating revisions as those events unfold. Investors should also watch consumables pull-through, cash burn and liquidity, competitive product launches, and any changes in federal research funding policy, all of which are central to whether the stock can sustain a move toward $2.70. From what I see, monitoring these factors closely helps clarify the setup.

Using AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile name like PACB, this kind of systematic, real-time monitoring can help traders spot shifting trends, discover new opportunities, and manage existing positions more efficiently than manual screening alone. Traders looking to complement fundamental research with automated, data-driven signals can explore the platform to see how the tool applies to their watchlist.

Final Assessment

Reaching $2.70 — the average of six current analyst targets spanning $2.00 to $3.00 — would require Pacific Biosciences shares to gain roughly 48% from recent levels near $1.82. The case rests on a genuine, if early, operational inflection in instruments and consumables, the cost-lowering potential of SPRQ-Nx, and expanding clinical adoption. Against that stand persistent cash burn, heavy convertible debt, intense competition, and the near-term risk of a demand pause flagged by the most cautious analyst. With targets and ratings spread from Underweight to Buy, the range itself is the story: the market is still pricing in significant uncertainty about whether PacBio's long-term opportunity will translate into durable, funded growth. Investors should monitor the SPRQ-Nx launch, consumables trends, and the next earnings report before drawing conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PACB

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


PACB sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 226 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 109 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for PACB moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 27 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In 74 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

PACB moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

PACB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-21.104) is slightly lower than the industry average of (4.142). P/E Ratio (-5.369) is within average values for comparable stocks, (3.291). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of sequencing system products to help scientists to resolve genetically complex problems

Industry MedicalNursingServices

Industry
Biotechnology
Address
1305 O’Brien Drive
Phone
+1 650 521-8000
Employees
485
Web
https://www.pacb.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.